GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization - Takeaways - MDSpire

GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization

  • By

  • Aditya Mahadevan

  • Aidan Vosooghi

  • Jagmeet S Arora

  • Ruthvik Sunil Kumar

  • Gagandeep Singh

  • Katy K Tsai

  • Zoe Quandt

  • January 2, 2026

  • 0 min

Share

  • 1

    GLP-1 receptor agonists (GLP-1RAs) are associated with lower all-cause mortality in cancer patients with type 2 diabetes compared to metformin.

  • 2

    Patients receiving GLP-1RAs demonstrated significantly reduced hospitalization rates and fewer major adverse cardiovascular events.

  • 3

    The study utilized a large database of over 120 million patients to analyze outcomes in 3747 patients on GLP-1RAs and 52,061 on metformin.

  • 4

    Subanalyses showed that patients newly started on GLP-1RAs had superior survival outcomes compared to those newly started on insulin.

  • 5

    Further research is needed to confirm the benefits of GLP-1RAs in patients with diabetes and active cancer.

Original Source(s)

GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization

  • by Aditya Mahadevan, Aidan Vosooghi, Jagmeet S Arora, Ruthvik Sunil Kumar, Gagandeep Singh, Katy K Tsai, Zoe Quandt

  • January 2, 2026

Related Content

Surgical outcomes of Bethesda System for Reporting Thyroid Cytopathology diagnostic category class I, II, and III thyroid nodules

What RVO May Reveal About Systemic Health

TriNetX data presented at Retina World Congress linked BRVO and CRVO with increased risks of stroke, myocardial infarction, and carotid disease.

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?